KIFFIK Biomedical Establishes Strategic Partnership with Beacon MedTech Solutions to Commercialize its K-EXP™ Platform
Clinical device expected availability in 2026 Scalable platform launch planned for 2027 [ MIAMI ] — KIFFIK Biomedical Inc. (“KIFFIK”), a leader in interstitial fluid (ISF)-based diagnostics, today announced a strategic manufacturing partnership with Beacon MedTech Solutions to deliver its K-EXP™ platform. The K-EXP™ clinical device is expected to be available in the second half of 2026, with the scalable production of its next-generation device beginning in mid-2027. The partnership marks a shift from development to execution, aligning clinical deployment and large-scale manufacturing within a single, continuous development timeline. “We …

KIFFIK Biomedical and HekaBio Announce Strategic Alliance to Expand ISF-Based Molecular Access Across Asia-Pacific
The K-EXP™ platform enables direct access to interstitial fluid for molecular measurement at the source Partnership supports regulatory, clinical, and commercial expansion across Japan and Asia-Pacific [ MIAMI, FL AND TOKYO, JAPAN / ACCESS Newswire ] – KIFFIK Biomedical today announced a strategic alliance with HekaBio K.K. to expand access to interstitial fluid (ISF) across Japan and key Asia-Pacific markets. ISF surrounds living cells and reflects real-time biological activity at the tissue level – where molecular signaling, immune response, and disease progression originate. KIFFIK’s K-EXP™ platform is designed to access …

KIFFIK Biomedical Closes Oversubscribed Series A to Advance Real-Time Molecular Diagnostics Platform
KIFFIK Biomedical announced today the successful close of its Series A financing, completed ahead of schedule and significantly oversubscribed. The strong demand reflects growing investor conviction that the future of diagnostics lies in continuous, real-time measurement of human biology rather than episodic blood-based testing.    The round was led by a group of global strategic investors aligned around a shared thesis: healthcare is entering a new era where dynamic molecular data will be essential for earlier disease detection, therapy optimization, and next-generation drug development. Proceeds from the financing will support the expansion …

Unlocking the Potential of Interstitial Fluid (ISF) Biomarkers
Transforming Drug Development, Diagnostics & Patient Care For decades, blood has been the dominant biofluid for biomarker discovery, diagnostics, and therapeutic monitoring. While valuable, blood comes with limitations: delayed signals, systemic ‘noise,’ invasive sampling, and constraints on frequency. Interstitial fluid (ISF), the fluid that surrounds every cell in the body, offers a complementary and, in many cases, superior alternative. ISF captures molecular changes at the tissue level where disease begins and where drugs act. Advances in minimally invasive sampling technologies now make ISF accessible at scale, opening new possibilities across …

KIFFIK Biomedical Onboards Industry Leader Rene Veloso
Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operations. Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operations. August 13, 2025  MDL Strategic Communications PROVIDENCE, RI, August, 12, 2025- KIFFIK Biomedical, Inc. (“Kiffik”), a leader in interstitial fluid (ISF)-based diagnostics, today announced a new appointment to its leadership team. Healthcare development executive Rene Veloso joins as Chief Investment Officer (CIO). Rene Veloso Chief Investment Officer “The addition of Rene to our already …

Tapping into the body’s ISF ‘superhighway’ for early disease detection
By extracting and analyzing biomarker data in interstitial fluid (ISF), we can better detect and treat a range of diseases much earlier. June 3, 2025  Medical Design & Outsourcing Pending FDA approval, the Kiffik Lab will be commercially available for at-home colorectal cancer testing in mid-2026. [Image courtesy of Kiffik Biomedical] In the mid-1800s, British physician Dr. Henry Bence Jones began testing the blood and urine of patients to look for signs of a protein indicative of multiple myeloma. Bence Jones is credited as being the first to explore biomarker …

KIFFIK Biomedical partners with Duracell
Powering the Future of Diagnostics PHTA’s first resident, KIFFIK Biomedical, is changing the diagnostics landscape with a needle-free, interstitial fluid (ISF)-based diagnostic platform, the KIFFIK Lab™ – offering fast, accurate, and at-home disease detection. Now, through a strategic partnership with Duracell, KIFFIK is accelerating the next generation of biomarker-driven diagnostics. This collaborations, supported by the PHTA ecosystem, is not just advancing cancer screening but also opening doors for broader industry innovation. “At KIFFIK, we believe that the future of diagnostics lies in harnessing the rich biomarker profile of interstitial fluid. …

Global Partnership with Duracell Batteries to Power New, Innovative Health Monitoring Technology
Duracell® batteries will be integrated into KIFFIK Biomonitoring Devices, such as health monitors, that detect various biomarkers in the body. [Providence, RI, 01/29/2025] – KIFFIK Biomedical and Duracell U.S. Operations, Inc. (“Duracell”) have agreed to collaborate and assess the integration of long-lasting, efficient power solutions with cutting-edge biomonitoring technology. This is good news for patients and the public communities, as the partnership’s goal is to enhance the precision and dependability of health monitoring systems around the globe, ultimately benefitting users in hospitals, high-performance sports, the military, and at home with …
21Dec

December News
KIFFIK Biomedical secures a pivotal $50 million investment from GEM Global Yield, positioning the company as a ‘Unicorn-in-Waiting’ KIFFIK’s patented platform will disrupt current MedTech markets by offering real-time insights and personalized care in a way that was previously unimaginable while allowing healthcare professionals to fully diagnose, monitor, and more extensively treat patients remotely. Read More > “I’m excited to announce a major milestone for KIFFIK Biomedical. We want to thank our new partners GEM, as we continue to deliver on our mission of bringing promising new diagnostic advancements to …

Kiffik is on the verge of transforming the future of healthcare
The interstitial space is the primary source of lymph and is a major fluid compartment in the body. While the anatomy and composition of the interstitial space between cells is increasingly understood, the existence, location, and structure of larger inter- and intra-tissue spaces is described only vaguely in the literature.
Kiffik Biomedical
Navigation
FOLLOW US
Linkedin Youtube Instagram